CCIA
NKTR icon

Campbell & Co Investment Adviser’s Nektar Therapeutics NKTR Stock Holding History

Campbell & Co Investment Adviser’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-5,352
Closed -$883K – 213
2015
Q1 		$883K Buy
+5,352
New +$1.1M 0.56% 65

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Campbell & Co Investment Adviser's NKTR Position: Q2 2015 in Review

Campbell & Co Investment Adviser sold out of Nektar Therapeutics (NKTR) in Q2 2015, closing a stake of 5,352 shares — an estimated $883K sold.

Campbell & Co Investment Adviser first reported a position in NKTR in Q1 2015 and held it in 1 quarter. The position peaked at $883K in Q1 2015. 181 funds tracked by Wall St. Rank hold NKTR as of Q2 2015.

  • Campbell & Co Investment Adviser reported no remaining Nektar Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 5,352 Nektar Therapeutics shares in Q2 2015, an estimated $883K.
  • Campbell & Co Investment Adviser first reported a position in Nektar Therapeutics in Q1 2015 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Nektar Therapeutics position peaked at $883K in Q1 2015.
  • 181 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2015.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2015, filed 7 Aug 2015.